Gregorc, V., Gaafar, R. M., Favaretto, A., Grossi, F., Jassem, J., Polychronis, A., Bidoli, P., Tiseo, M., Shah, R., Taylor, P., Novello, S., Muzio, A., Bearz, A., Greillier, L., Fontana, F., Salini, G., Lambiase, A., & O'Brien, M. (2018). nGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet oncology, 19(6), 799–811. http://access.bl.uk/ark:/81055/vdc_100065599900.0x00000f